Direkt zum Inhalt
Merck
  • Demography and treatment response in patients with predominant non-erosive reflux disease or functional dyspepsia.

Demography and treatment response in patients with predominant non-erosive reflux disease or functional dyspepsia.

Journal of gastroenterology and hepatology (2015-01-07)
Hiroto Miwa, Ken Haruma, Shigeru Sakamoto, Katsuyuki Sanada, Shinzo Hiroi, Yoshikazu Kinoshita
ZUSAMMENFASSUNG

Non-erosive reflux disease (NERD) and functional dyspepsia (FD) share some common features, and the appropriateness of managing these diseases independently has been questioned. A post-hoc subgroup analysis of the LEGEND study was performed to compare demographics and treatment response between patients with NERD and patients with FD. Patients with reflux and dyspepsia symptoms who had no endoscopic evidence of mucosal breaks and/or erosions were included and divided into groups with predominant NERD (n = 1546) or FD (n = 614). Patients received lansoprazole for 4 weeks, and their symptoms were evaluated using questionnaires. FD patients were significantly younger than NERD patients (54 vs 60 years), more likely to have a body mass index < 25 kg/m(2) (72.4% vs 67.1%), less likely to have a hiatal hernia (24.0% vs 31.2%), and more likely to feel continuous stress (54.7% vs 48.0%). After 4 weeks of treatment, > 60% of both patients reported an improvement in reflux symptoms and in most dyspepsia symptoms. The improvement rate for reflux symptoms was lower in FD patients than in NERD patients (P < 0.05), whereas the improvement rate for dyspepsia symptoms did not differ between patient groups. Although no clinically significant differences in pathophysiology exist between NERD and FD, there are some between-group differences in demographic characteristics and improvement rates for reflux symptoms after treatment with lansoprazole. It remains to be discussed whether it is necessary to make a strict differential diagnosis between these two conditions.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Lansoprazol, ≥98% (TLC), powder
USP
Lansoprazol, United States Pharmacopeia (USP) Reference Standard
Lansoprazol, European Pharmacopoeia (EP) Reference Standard
Lansoprazol für die Peakidentifizierung, European Pharmacopoeia (EP) Reference Standard